Ann: Lumos Appoints Henry Schein as US Distributor for FebriDx, page-77

Article in Afr

https://www.copyright link/wealth/personal-finance/why-analysts-love-these-eight-medtech-stocks-20240206-p5f2r2


Lumos: The company sells diagnostic tests to help healthcare professionals manage patients’ medical conditions. Smith likes its outlook and says recent capital raisings mean it has the cash runway to deliver on its potential after the stock performed poorly since its initial public offer in 2021.

“The management team have worked to right-size the business and put themselves in a strong strategic position with their services business to generate cash,” says Smith. “We see this cash generation assisting the acceleration of growth in their product business over the next 18 months which should drive a re-rate in the share price.”